PE20151535A1 - Derivado de dihidropiridazin-3,5-diona - Google Patents

Derivado de dihidropiridazin-3,5-diona

Info

Publication number
PE20151535A1
PE20151535A1 PE2015001917A PE2015001917A PE20151535A1 PE 20151535 A1 PE20151535 A1 PE 20151535A1 PE 2015001917 A PE2015001917 A PE 2015001917A PE 2015001917 A PE2015001917 A PE 2015001917A PE 20151535 A1 PE20151535 A1 PE 20151535A1
Authority
PE
Peru
Prior art keywords
methyl
trifluoromethyl
phenyl
diona
compounds
Prior art date
Application number
PE2015001917A
Other languages
English (en)
Inventor
Yoshihito Ohtake
Naoki Okamoto
Yoshiyuki Ono
Hirotaka Kashiwagi
Atsushi Kimbara
Takeo Harada
Nobuyuki Hori
Yoshihisa Murata
Kazutaka Tachibana
Shota Tanaka
Kenichi Nomura
Mitsuaki Ide
Eisaku Mizuguchi
Yasuhiro Ichida
Shuichi Ohtomo
Naoshi Horiba
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20151535A1 publication Critical patent/PE20151535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE DIHIDROPIRIDAZIN-3,5-DIONA DE FORMULA (I) DONDE R1, R3, R4, R5 Y Ar1 SON TAL COMO SE DEFINE EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (4aR)-1-[(2,3-DIFLUOROFENIL)METIL]-4-HIDROXI-4a-METIL-2-OXO-N-[4-(TRIFLUOROMETIL)-2-[6-(TRIFLUOROMETIL)PIRIMIDIN-4-IL]FENIL]-6,7-DIHIDRO-5H-PIRROLO[1,2-b]PIRIDAZIN-3-CARBOXAMIDA; (4aR)-N-[2-(6-CIANO-5-METILPIRIMIDIN-4-IL)-4-(TRIFLUOROMETIL)FENIL]-1-[[2,3-DIFLUORO-4-(2-MORFOLIN-4-ILETOXI)FENIL]METIL]-4-HIDROXI-4a-METIL-2-OXO-6,7-DIHIDRO-5H-PIRROLO[1,2-b]PIRIDAZIN-3-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE FOSFATO DEPENDIENTE DE SODIO SIENDO UTILES PARA EL TRATAMIENTO DE HIPERFOSFATEMIA, INSUFICIENCIA RENAL CRONICA
PE2015001917A 2013-03-13 2014-03-13 Derivado de dihidropiridazin-3,5-diona PE20151535A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25

Publications (1)

Publication Number Publication Date
PE20151535A1 true PE20151535A1 (es) 2015-10-28

Family

ID=51536921

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001917A PE20151535A1 (es) 2013-03-13 2014-03-13 Derivado de dihidropiridazin-3,5-diona

Country Status (30)

Country Link
EP (2) EP2975030B1 (es)
JP (2) JP5814488B2 (es)
KR (2) KR102072268B1 (es)
CN (1) CN105073715B (es)
AU (1) AU2014230552B2 (es)
BR (1) BR112015022092B1 (es)
CA (1) CA2901868C (es)
CL (1) CL2015002543A1 (es)
CR (1) CR20150505A (es)
DK (1) DK2975030T3 (es)
ES (1) ES2811126T3 (es)
HK (1) HK1212700A1 (es)
HR (1) HRP20201211T1 (es)
HU (1) HUE050577T2 (es)
IL (1) IL240825B (es)
LT (1) LT2975030T (es)
MX (1) MX2015012537A (es)
MY (1) MY174269A (es)
NZ (1) NZ711182A (es)
PE (1) PE20151535A1 (es)
PH (1) PH12015501940B1 (es)
PL (1) PL2975030T3 (es)
PT (1) PT2975030T (es)
RS (1) RS60911B1 (es)
RU (1) RU2662832C2 (es)
SG (1) SG11201507345RA (es)
SI (1) SI2975030T1 (es)
TW (2) TWI596095B (es)
UA (1) UA118755C2 (es)
WO (1) WO2014142273A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102072268B1 (ko) * 2013-03-13 2020-01-31 추가이 세이야쿠 가부시키가이샤 디하이드로피리다진-3,5-디온 유도체
MX2017002737A (es) * 2014-09-12 2017-05-19 Chugai Pharmaceutical Co Ltd Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料（常州）有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
BR112022026083A2 (pt) 2020-06-26 2023-01-17 Nihon Nohyaku Co Ltd Derivado de ariltetra-hidropiridazina ou sal do mesmo, agente inseticida contendo o composto, e método de uso do mesmo
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
AU2022288895A1 (en) 2021-06-08 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Formulation containing dihydropyridazine-3,5-dione derivative
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307780A (pt) * 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
AR055057A1 (es) * 2005-05-18 2007-08-01 Array Biopharma Inc Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria.
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
KR20090080108A (ko) * 2006-11-03 2009-07-23 바스프 에스이 디플루오로메틸피라졸릴 카르복실레이트의 제조 방법
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN102264740B (zh) * 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
PT2565190E (pt) * 2010-04-28 2015-08-24 Astellas Pharma Inc Composto de tetra-hidrobenzotiofeno
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827327B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP6020460B2 (ja) 2011-10-27 2016-11-02 アステラス製薬株式会社 アミノアルキル置換ｎ−チエニルベンズアミド誘導体
KR102072268B1 (ko) * 2013-03-13 2020-01-31 추가이 세이야쿠 가부시키가이샤 디하이드로피리다진-3,5-디온 유도체

Also Published As

Publication number Publication date
MX2015012537A (es) 2016-02-10
HUE050577T2 (hu) 2020-12-28
CA2901868C (en) 2022-05-03
KR20160119282A (ko) 2016-10-12
EP2975030A4 (en) 2016-08-03
DK2975030T3 (da) 2020-08-31
AU2014230552A1 (en) 2015-08-13
JP2016040262A (ja) 2016-03-24
CL2015002543A1 (es) 2016-02-26
KR102072268B1 (ko) 2020-01-31
EP2975030A1 (en) 2016-01-20
CR20150505A (es) 2015-10-26
JPWO2014142273A1 (ja) 2017-02-16
LT2975030T (lt) 2020-09-25
HK1212700A1 (zh) 2016-06-17
TW201446756A (zh) 2014-12-16
JP5814488B2 (ja) 2015-11-17
SI2975030T1 (sl) 2020-10-30
IL240825B (en) 2020-07-30
RU2662832C2 (ru) 2018-07-31
TWI596095B (zh) 2017-08-21
SG11201507345RA (en) 2015-10-29
BR112015022092A2 (pt) 2017-07-18
RU2015143507A (ru) 2017-04-19
BR112015022092B1 (pt) 2023-04-11
KR101664460B1 (ko) 2016-10-10
PL2975030T3 (pl) 2021-01-11
PH12015501940A1 (en) 2016-01-11
BR112015022092A8 (pt) 2018-01-23
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
IL240825A0 (en) 2015-10-29
KR20150127721A (ko) 2015-11-17
WO2014142273A1 (ja) 2014-09-18
EP2975030B1 (en) 2020-07-15
MY174269A (en) 2020-04-01
EP3757093A1 (en) 2020-12-30
CA2901868A1 (en) 2014-09-18
NZ711182A (en) 2020-05-29
HRP20201211T1 (hr) 2020-11-13
ES2811126T3 (es) 2021-03-10
AU2014230552B2 (en) 2017-11-16
CN105073715A (zh) 2015-11-18
RS60911B1 (sr) 2020-11-30
TW201741304A (zh) 2017-12-01
CN105073715B (zh) 2017-12-01
PT2975030T (pt) 2020-09-28
PH12015501940B1 (en) 2016-01-11
JP6420738B2 (ja) 2018-11-07

Similar Documents

Publication Publication Date Title
PE20151535A1 (es) Derivado de dihidropiridazin-3,5-diona
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790661A2 (ru) Ингибиторы вируса гепатита c
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
JO3425B1 (ar) مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
PE20161476A1 (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
NZ727185A (en) Phosphatidylinositol 3-kinase inhibitors
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
CY1119687T1 (el) Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης
EA201600435A1 (ru) Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора